Last reviewed · How we verify

Methylprednisolone and IVIG

The Hospital for Sick Children · Phase 3 active Small molecule

Methylprednisolone and IVIG is a Combination immunosuppressant and immunomodulator Small molecule drug developed by The Hospital for Sick Children. It is currently in Phase 3 development for Autoimmune or inflammatory conditions in pediatric patients (specific indication context-dependent on trial design). Also known as: Solumedrol.

Methylprednisolone suppresses immune inflammation via glucocorticoid receptor signaling, while IVIG provides immunomodulation through Fc receptor engagement and anti-inflammatory pathways.

Methylprednisolone suppresses immune inflammation via glucocorticoid receptor signaling, while IVIG provides immunomodulation through Fc receptor engagement and anti-inflammatory pathways. Used for Autoimmune or inflammatory conditions in pediatric patients (specific indication context-dependent on trial design).

At a glance

Generic nameMethylprednisolone and IVIG
Also known asSolumedrol
SponsorThe Hospital for Sick Children
Drug classCombination immunosuppressant and immunomodulator
TargetGlucocorticoid receptor (methylprednisolone); Fc receptors and complement (IVIG)
ModalitySmall molecule
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

Methylprednisolone is a corticosteroid that reduces inflammatory cytokine production and immune cell activation. IVIG (intravenous immunoglobulin) modulates immune responses through multiple mechanisms including Fc receptor blockade, complement inhibition, and anti-inflammatory signaling. Together, this combination targets both innate and adaptive immune dysregulation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Methylprednisolone and IVIG

What is Methylprednisolone and IVIG?

Methylprednisolone and IVIG is a Combination immunosuppressant and immunomodulator drug developed by The Hospital for Sick Children, indicated for Autoimmune or inflammatory conditions in pediatric patients (specific indication context-dependent on trial design).

How does Methylprednisolone and IVIG work?

Methylprednisolone suppresses immune inflammation via glucocorticoid receptor signaling, while IVIG provides immunomodulation through Fc receptor engagement and anti-inflammatory pathways.

What is Methylprednisolone and IVIG used for?

Methylprednisolone and IVIG is indicated for Autoimmune or inflammatory conditions in pediatric patients (specific indication context-dependent on trial design).

Who makes Methylprednisolone and IVIG?

Methylprednisolone and IVIG is developed by The Hospital for Sick Children (see full The Hospital for Sick Children pipeline at /company/the-hospital-for-sick-children).

Is Methylprednisolone and IVIG also known as anything else?

Methylprednisolone and IVIG is also known as Solumedrol.

What drug class is Methylprednisolone and IVIG in?

Methylprednisolone and IVIG belongs to the Combination immunosuppressant and immunomodulator class. See all Combination immunosuppressant and immunomodulator drugs at /class/combination-immunosuppressant-and-immunomodulator.

What development phase is Methylprednisolone and IVIG in?

Methylprednisolone and IVIG is in Phase 3.

What are the side effects of Methylprednisolone and IVIG?

Common side effects of Methylprednisolone and IVIG include Infection (opportunistic or bacterial), Hyperglycemia, Hypertension, Headache, Infusion reactions, Immunosuppression-related complications.

What does Methylprednisolone and IVIG target?

Methylprednisolone and IVIG targets Glucocorticoid receptor (methylprednisolone); Fc receptors and complement (IVIG) and is a Combination immunosuppressant and immunomodulator.

Related